AUTHOR=Zhang Jun , Li Yang TITLE=Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders JOURNAL=Frontiers in Endocrinology VOLUME=6 YEAR=2015 URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2015.00168 DOI=10.3389/fendo.2015.00168 ISSN=1664-2392 ABSTRACT=

Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents.